Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
Kelsey Musselman, Shannon Glynn, Juan Miguel Mosquera and 4 more
Gynecologic Oncology Reports · 2019
doi:10.1016/j.gore.2019.01.013 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Uterine serous adenocarcinoma is a rare but highly malignant form of endometrial cancer, comprising over 50% of recurrences and deaths from endometrial cancer. We report a case of a 68-year old woman with recurrent uterine serous adenocarcinoma who underwent molecular testing and genetic sequencing of her tumor. She was found to have focal amplification of ERBB2 confirmed by amplification and overexpression of HER2/neu via fluorescence in situ hybridization and immunohistochemistry. Given the identification of this potential target and progression of disease, trastuzumab was added to the patient's chemotherapy regimen with ultimate complete response. Keywords: Uterine papillary serous carcinoma, Trastuzumab, Precision medicine, Genetic sequencing, HER2/neu, Uterine serous adenocarcinoma, uterine serous carcinoma
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.